GlassScriptPhysician profile
Richard S Winer
NPI 1164567277
$103,372.38
in general payments reported to CMS, 2019-2025
49 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $932 · 2021: $8,131 · 2022: $18K · 2023: $30K · 2024: $22K · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $4,996 · Food and Beverage: $3,266 · Honoraria: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,905.00 |
| Travel and Lodging | $4,996.11 |
| Food and Beverage | $3,265.79 |
| Honoraria | $3,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $56,182.40 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $15,666.59 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $8,080.44 | 2023-2024 | Quviviq |
| Shire North American Group INC | $8,012.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $6,538.37 | 2021-2022 | |
| Tris Pharma INC | $4,044.86 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $688.98 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $598.52 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $531.88 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $489.27 | 2019-2025 | Trintellix |
| Amgen INC. | $321.09 | 2019-2023 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $299.34 | 2020-2024 | Rexulti |
| Amarin Pharma, INC. | $201.01 | 2020-2022 | |
| Lundbeck LLC | $182.26 | 2020-2025 | Rexulti |
| Eisai INC. | $168.89 | 2020-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Winer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.